Breast Cancer Research Centre-WA

Nedlands 6009

0 studies enrolling now · 4 studies all time

What they study most

Breast Neoplasms, Estrogen Receptor Positive Breast Cancer, HER-2 Positive Breast Cancer, HER2-Positive Primary Breast Cancer, HER2-positive Breast Cancer, Residual Invasive Breast Cancer

Studies at this site

• A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer — Running, not enrolling
• A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) — Running, not enrolling
• A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer — Running, not enrolling
• Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer — Running, not enrolling